Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001867
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Effect of Pregnancy on Uveitis
Sponsor:
National Eye Institute NEI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Effect of Pregnancy on Uveitis
Status:
COMPLETED
Status Verified Date:
1999-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to gain information about the course of uveitis a type of eye inflammation during pregnancy and the postpartum period six months after delivery Some reports have indicated the condition may improve or disappear without treatment during pregnancy and recur postpartum requiring treatment No systematic studies have been done however to examine a link between pregnancy and disease suppression
All medicines for uveitis have side effects-particularly for pregnant women their unborn babies and breast-feeding mothers The information gained may help guide treatment decisions for these patients in the future
Women who are between 2 and 20 weeks pregnant and have had uveitis within 2 years of becoming pregnant will be followed monthly with an eye examination and blood tests until six months after giving birth The eye examination will include dilation of the pupils to look at the back of the eye Photos of the eye will be taken to record changes that occur due to uveitis The blood tests will assess immune function and try to determine whether levels of hormones and cytokines are related to uveitis disease activity Patients who develop an inflammation and significant vision loss may require treatment possibly with eye drops or injections near the eye Treatment will be decided in consultation with the patients obstetrician
All medicines for uveitis have side effects-particularly for pregnant women their unborn babies and breast-feeding mothers The information gained may help guide treatment decisions for these patients in the future
Women who are between 2 and 20 weeks pregnant and have had uveitis within 2 years of becoming pregnant will be followed monthly with an eye examination and blood tests until six months after giving birth The eye examination will include dilation of the pupils to look at the back of the eye Photos of the eye will be taken to record changes that occur due to uveitis The blood tests will assess immune function and try to determine whether levels of hormones and cytokines are related to uveitis disease activity Patients who develop an inflammation and significant vision loss may require treatment possibly with eye drops or injections near the eye Treatment will be decided in consultation with the patients obstetrician
Detailed Description:
Pregnancy is thought to be associated with the remediation of some disease and exacerbation of other conditions Anecdotal case reports suggest that uveitis may remit or improve during pregnancy and recur in the postpartum period This observation is supported by findings in an experimental autoimmune uveitis model in mice We propose to study the natural history of ocular inflammation in a series of pregnant women who have had ocular inflammation uveitis in the two year period prior to becoming pregnant Women will be enrolled between 2 and 20 completed weeks of gestation at which time they will receive a complete ophthalmologic examination and will have blood drawn for cytokine and hormone evaluation These procedures will be repeated at monthly intervals until 6 months postpartum Treatment of uveitis will ensue as medically indicated and in consultation with the womans obstetric care provider The goal of this investigation is to determine whether cytokine levels are correlated with disease expression Such information may be useful to inform decisions about how to best manage pregnant and postpartum uveitis patients in the future
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 99-EI-0179 | None | None | None |